Design and synthesis of novel inhibitors of the p53-Mdm2 interaction and the development of novel inhibitors of cyclin dependent kinases
The disruption of the p53-Mdm2 interaction is an attractive therapeutic strategy for activating p53 tumour suppressor activity in tumours expressing wild type p53. One such strategy for the disruption of the P53-Mdm2 interaction is the design of low molecular weight ligands that bind at the p53-Mdm2...
Main Author: | |
---|---|
Published: |
University of Edinburgh
2004
|
Subjects: | |
Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.641199 |